Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Mersana Therapeutics Inc (0M4.SG)

Compare

0.4837

-0.0195

(-3.88%)

At close: February 21 at 9:32:08 PM GMT+1

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on February 3, 2025, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 20,610 shares of its common

GlobeNewswire 16 days ago

MRSN
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investo

GlobeNewswire 24 days ago

MRSN
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events reported. At intermediate doses in the trial (38.1 mg/m2 to 67.4 mg/m2), the confirmed objective response rate among evaluable patients was 23% (6 of 26 patients) across all B7-H4 high tumors and 23% (3 of 13 patients) with B7-H4 high TNBC, all of whom had

Benzinga last month

MRSN
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to XMT-1660. The compa

GlobeNewswire last month

MRSN
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile- Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously treated with topoisomerase-1 inhibitor (topo-1) ADCs; confirmed responses observed across all enrolled tumor types- First expansion cohort initiated in patients with TNBC previously treated with at least one topo-1 ADC; dose exploration efforts ongoing- Company announces expected 20

GlobeNewswire last month

MRSN
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Mersana Therapeutics Inc (MRSN) reports significant financial improvements and promising clinical trial progress, positioning the company for future growth.

GuruFocus.com 3 months ago

MRSN
Q3 2024 Mersana Therapeutics Inc Earnings Call

Q3 2024 Mersana Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

MRSN
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 50% and 32.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

MRSN
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business updat

GlobeNewswire 3 months ago

MRSN
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8

GlobeNewswire 3 months ago

MRSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mersana Therapeutics, Inc. ( NASDAQ:MRSN ) missed earnings with its latest second-quarter results, disappointing...

Simply Wall St. 6 months ago

MRSN
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -11.11% and 72.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

MRSN
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeli

GlobeNewswire 6 months ago

MRSN
Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m.

GlobeNewswire 6 months ago

MRSN
Mersana Therapeutics (NASDAQ:MRSN) shareholders have endured a 83% loss from investing in the stock three years ago

As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...

Simply Wall St. 6 months ago

MRSN
Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation SummitFormat: Fireside chatDate/Time: Wednesday, May 29, 2024, at 9:00 a.m. East

GlobeNewswire 8 months ago

MRSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript May 9, 2024 Mersana Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Mersana Therapeutics First Quarter 2024 Conference Call and Webcast. Currently, all […]

Insider Monkey 9 months ago

MRSN
Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis

Insights into Mersana Therapeutics' Performance and Strategic Updates

GuruFocus.com 9 months ago

MRSN
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 9 months ago

MRSN
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mas

GlobeNewswire 9 months ago

MRSN

Performance Overview

Return	0M4.SG	S&P 500
YTD	-65.38%	+2.24%
1-Year	-85.36%	+20.70%
3-Year	-84.40%	+38.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mersana Therapeutics Inc (0M4.SG)

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Q3 2024 Mersana Therapeutics Inc Earnings Call

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

Mersana Therapeutics (NASDAQ:MRSN) shareholders have endured a 83% loss from investing in the stock three years ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript

Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Performance Overview